Anthony G. Quinn, President & CEO at Aeglea BioTherapeutics, Inc. (AGLE), bought 58,528 shares at $6.17 ($360K) on 2019-06-13, disclosed to the SEC on 2019-06-14.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.11 | 12,217 | $75K | 20.7% |
| 2 | $6.11 | 12,217 | $75K | 20.7% |
| 3 | $6.17 | 14,406 | $89K | 24.7% |
| 4 | $6.17 | 14,406 | $89K | 24.7% |
| 5 | $6.23 | 5,282 | $33K | 9.1% |
| Total | $6.15 avg | 58,528 |
| $360K |
| 100% |
| Filing → |
| AGLE | BUY | 2022-03-18 | $375K | — | Filing → |
| AGLE | BUY | 2022-03-15 | $562K | — | Filing → |
| AGLE | BUY | 2021-12-13 | $358K | — | Filing → |